Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
KING OF PRUSSIA, Pa., March 14, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 1:35 p.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
